What is USFDA Tentative Approval?

If a generic drug product is ready for approval before the expiration of any patents or exclusivities accorded to the reference listed drug product, FDA issues a tentative approval letter to the applicant. The tentative approval letter details the circumstances associated with the tentative approval. FDA delays final approval of the generic drug product until all patent or exclusivity issues have been resolved.

A Tentative Approval (TA) by the U.S. Food and Drug Administration (USFDA) refers to a preliminary approval granted to a generic drug application, known as an Abbreviated New Drug Application (ANDA), indicating that the product has met all regulatory standards for quality, safety, and efficacy. However, this approval does not grant the applicant permission to market the drug in the United States until certain conditions are met.

Keynotes about USFDA tentative approval:

• A tentative approval does not allow the applicant to market the generic drug product.
• Tentative approval is granted by the FDA if an ANDA meets the substantive requirements for approval but cannot obtain final approval due to unexpired patents or exclusivities.
• To gain final approval, applicants may submit changes to the application, request final approval, or propose changes and request final approval through amendments. The nature of these amendments may delay final approval of the ANDA until after the earliest lawful ANDA approval date. A drug product may not be marketed until the ANDA gains final Agency approval.

Requesting Final Approval for Tentatively Approved ANDAs

• When an amendment is submitted to a tentatively approved ANDA, FDA has the option to assess the amendment or defer it. If the Agency decides to assess the amendment, the status of the submitted ANDA will be changed from “TA” to “under review”.
• After review, if the ANDA meets all requirements for final approval, approval will be granted by the Agency.
• If the amendment has not resolved all deficiencies, the status of the ANDA will be converted to a complete response status as communicated in the complete response letter (CRL). The complete response status will remain in effect until the deficiencies are addressed in a subsequent amendment and FDA reinstates TA or grants final approval.

Benefits of Tentative Approval:

• For the Generic Company: HealthGen can start generating revenue internationally and build a presence in global health markets.
• For Patients and Health Programs: Affordable access to essential medications for life-threatening conditions is facilitated in regions where they are most needed.
• For the FDA and Global Health: Ensures that only high-quality, rigorously reviewed products are used in global health initiatives.

Key Aspects of Tentative Approval:

Regulatory and Patent Compliance:

A Tentative Approval is issued when the drug meets all necessary regulatory requirements but is subject to patent exclusivity or legal restrictions, such as market exclusivity held by the brand-name product or other exclusivity rights (e.g., 180-day exclusivity for the first generic to file).

International Implications:

Tentative Approval is significant for international programs such as the President’s Emergency Plan for AIDS Relief (PEPFAR), which allows generic drugs to be used in other countries before final approval in the U.S. This facilitates access to essential medicines in low- and middle-income countries.

Final Approval Pending:

The Tentative Approval remains in effect until the blocking exclusivity or patent expires, after which the FDA can issue a Final Approval. Once granted, the company can then market the drug in the U.S.

Labeling and Marketing:

Until Final Approval, the product cannot be marketed or sold in the United States, but applicants often use the tentative approval to support approvals or funding in international markets.

Example Scenario

Suppose a generic company submits an ANDA for a drug still under patent protection by the innovator company. The FDA may grant a Tentative Approval, confirming that the generic product is ready for approval but must wait until the patent protection period expires.

Tentative Approval allows the FDA to provide early support for a product while ensuring compliance with all necessary intellectual property and exclusivity requirements.